Tenaya Therapeutics (NASDAQ:TNYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript [Seeking Alpha]
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy [Yahoo! Finance]
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy